Orexo ABORXOF 34 Return-on-Tangible-Asset is -55.92% as of Mar. 2026. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Orexo AB ranks better than 99.3% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Orexo AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $-57.48 Mil. Orexo AB's average total tangible assets for the quarter that ended in Mar. 2026 was $102.81 Mil. Therefore, Orexo AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -55.92%.
The historical rank and industry rank for Orexo AB's Return-on-Tangible-Asset or its related term are showing as below:
ORXOF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -34.37 Med: -2.25 Max: 76.2
Current: 76.2
During the past 13 years, Orexo AB's highest Return-on-Tangible-Asset was 76.20%. The lowest was -34.37%. And the median was -2.25%.
ORXOF's Return-on-Tangible-Asset is ranked better than 99.3% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.09
vs ORXOF: 76.20
Orexo AB (OTCPK:ORXOF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Orexo AB Return-on-Tangible-Asset Related Terms
Orexo AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Orexo AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Orexo AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -55.92% mean?
Orexo AB (ORXOF) has a Return-on-Tangible-Asset of -55.92% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orexo AB and its competitors. According to the industry distribution chart, Orexo AB ranks #7 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is Orexo AB's Return-on-Tangible-Asset too high?
Orexo AB's current Return-on-Tangible-Asset is -55.92%. Based on the distribution chart, Orexo AB ranks #7 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #7 out of 1006 companies for Return-on-Tangible-Asset. This places Orexo AB in the top 1% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.09, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Return-on-Tangible-Asset is -55.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Return-on-Tangible-Asset is -55.92%. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Return-on-Tangible-Asset is -55.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
Return-on-Tangible-Asset: -55.92%
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
